You are here

Topiramate Trial in Obesity and Diabetes Discontinued

Raritan, NJ (December 1, 2004) – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a Johnson & Johnson company, announced today that it is discontinuing the current clinical development program for its controlled release formulation of topiramate in obesity and Type 2 diabetes.

A controlled release formulation of topiramate was specifically developed for study in obese individuals with Type 2 diabetes to potentially simplify dosing and enhance the compound's profile in order to create a better treatment option for patients. Data from a recently completed phase II clinical study with the controlled release formulation of topiramate showed that the controlled release formulation did not provide significant advantages in this population compared to previously conducted studies using the immediate release formulation.

This decision is not based on any new safety information and does not impact the use of topiramate, marketed as TOPAMAX® (topiramate/topiramate capsules), in any currently-approved indications or clinical development programs underway. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., remains committed to developing innovative medicines for the treatment of metabolic disease.

TOPAMAX® is marketed in the U.S. by Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, and is approved to treat various types of epileptic seizures in more than 95 countries and for the prevention of migraine headaches in more than 28 countries. For more information on TOPAMAX®, please see full prescribing information or visit

Source: Johnson and Johnson

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year